What can we expect from PPAR agonists in the treatment of NASH?

Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.
Play Video

PPAR (Peroxisome proliferator-activated receptor) agonists have great  promise in the therapeutic landscape of NASH (Non-alcoholic steatohepatitis). The role of PPARs in general have been demonstrated to have a significant role in lipid metabolism, glucose metabolism, inflammation, endothelial revascularization as well as the activation of hepatic stellate cells……

Prof. M. F. Abdelmalek

Prof. M. F. Abdelmalek

Manal F. Abdelmalek, MD, MPH is Director of Hepatology and institutional lead for investigator-initiated and industry-sponsored multicenter clinical studies, Mayo Clinic, USA. Until recently, she was tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at...


Subscribe Our Newsletter To Get the Lastest Updates